FogPharma’s Post

With the American Association for Cancer Research (AACR) in full swing, among the many press releases and announcements there were two that stood out for me and my colleague Joel Sandler, Ph.D. – those from Candel Therapeutics and Vincerx Pharma.    Both releases were for novel modalities. Both releases were preliminary results with limited data.   Both releases announced, “Positive Interim/Preliminary Data”.  In response, Candel’s share price shot up by nearly 300% (with initial after-hour trading reaching a stratospheric 500%!) while Vincerx cratered, losing nearly 80%.  What happened?  Please read on below for a full analysis. #oncology #AACR #oncologyresearch #biotech #biopharma #cancer #candeltx #vincerx

Allarity Therapeutics (NASDAQ: ALLR) Stock Plunges Amid Ovarian Cancer Trial Discontinuation https://lnkd.in/dJuChVHc #allarity #NASDAQ #stockmarket #stockmarketnews #BusinessNews #news #NewsAlert

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/gabi_27S #biotech #france #texas #oncology #artificialIntelligence

🚀 Presenting ADC Digest for April 2024! 🔬 💊Adcentrx Therapeutics to showcase Preclinical findings of Nectin-4 ADC Program at AACR Annual Meeting 2024 💊Datopotamab deruxtecan BLA accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer 💊Ipsen licenses Sutro ADC in $900m deal 💊Caris Life Sciences partners with Merck KGaA to discover cancer targets and fast-track ADC development Stay tuned for more updates and breakthroughs in the world of Antibody-Drug Conjugates! 💪🔬 #ADC #CancerResearch #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence

Explore the top targets and the number of products in the bispecific antibody space with curated analytics by LARVOL CLIN. 🧬 Stay ahead with detailed insights into the evolving landscape of antibody therapeutics. Explore more here: https://bit.ly/4bFSDpD #BispecificAntibodies #LARVOLCLIN #BiotechInsights #CancerData #Oncology

Summary of key XNK achievements in 2023 ▪️Approval of our manufacturing facility and tissue establishment. ▪️Delivery and presentation of preclinical data in our bladder cancer program. ▪️New pipeline project in liver cancer in collaboration with a global pharma. Even though the financial markets are challenging, we are really looking forward to 2024 and are convinced we will deliver great results! #nkcells #atmp #2023

Heidelberg Pharma AG, first in the world to develop amanitin for cancer therapy, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Heidelberg Pharma AG uses its proprietary ADC payload (ATAC® technology) to develop ADCs called ATACs that have amanitin-based compounds as the payload.     Why is Heidelberg Pharma AG a company to watch?  Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch 

Successful preclinical testing of your investigational cancer therapy depends on choosing the right model. Learn more by downloading our white paper! https://hubs.ly/Q02rJrvQ0 #Inotiv #Oncology #R2G2mouse

Multi-Omics/Multi-Dimensional data sets are needed to accelerate getting therapies to the clinic. Champions Oncology, Inc. have proven the value of advancing R&D with multi-omics/multi-dimensional data sets and are here to help the Pharmaceutical and Biotech industry do the same!